Uni-Bio Science Group (690) Stock Overview
An investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
690 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Uni-Bio Science Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.14 |
| 52 Week High | HK$0.17 |
| 52 Week Low | HK$0.051 |
| Beta | -0.019 |
| 1 Month Change | -14.55% |
| 3 Month Change | 39.60% |
| 1 Year Change | 80.77% |
| 3 Year Change | 74.07% |
| 5 Year Change | 2.17% |
| Change since IPO | -70.97% |
Recent News & Updates
Uni-Bio Science Group's (HKG:690) Weak Earnings May Only Reveal A Part Of The Whole Picture
Sep 04
Optimistic Investors Push Uni-Bio Science Group Limited (HKG:690) Shares Up 33% But Growth Is Lacking
Aug 18There's No Escaping Uni-Bio Science Group Limited's (HKG:690) Muted Earnings Despite A 32% Share Price Rise
Jul 03Recent updates
Uni-Bio Science Group's (HKG:690) Weak Earnings May Only Reveal A Part Of The Whole Picture
Sep 04Optimistic Investors Push Uni-Bio Science Group Limited (HKG:690) Shares Up 33% But Growth Is Lacking
Aug 18There's No Escaping Uni-Bio Science Group Limited's (HKG:690) Muted Earnings Despite A 32% Share Price Rise
Jul 03Is Uni-Bio Science Group (HKG:690) Using Too Much Debt?
Jun 12The CEO Of Uni-Bio Science Group Limited (HKG:690) Might See A Pay Rise On The Horizon
May 19Uni-Bio Science Group Limited's (HKG:690) Price Is Right But Growth Is Lacking After Shares Rocket 26%
May 07Uni-Bio Science Group Limited's (HKG:690) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Mar 13Is Uni-Bio Science Group (HKG:690) Using Too Much Debt?
Dec 11Uni-Bio Science Group Limited (HKG:690) Surges 35% Yet Its Low P/E Is No Reason For Excitement
Sep 13Earnings Working Against Uni-Bio Science Group Limited's (HKG:690) Share Price Following 26% Dive
Jul 29Earnings Working Against Uni-Bio Science Group Limited's (HKG:690) Share Price Following 27% Dive
May 27Is Uni-Bio Science Group (HKG:690) Using Too Much Debt?
Apr 24Uni-Bio Science Group Limited (HKG:690) Held Back By Insufficient Growth Even After Shares Climb 28%
Jan 22Uni-Bio Science Group Limited's (HKG:690) Low P/S No Reason For Excitement
Oct 24Robust Earnings May Not Tell The Whole Story For Uni-Bio Science Group (HKG:690)
Apr 30We're Interested To See How Uni-Bio Science Group (HKG:690) Uses Its Cash Hoard To Grow
Nov 22Estimating The Fair Value Of Uni-Bio Science Group Limited (HKG:690)
Jan 05Companies Like Uni-Bio Science Group (HKG:690) Can Afford To Invest In Growth
Mar 01Uni-Bio Science Group (HKG:690) Share Prices Have Dropped 26% In The Last Five Years
Jan 05
We're Interested To See How Uni-Bio Science Group (HKG:690) Uses Its Cash Hoard To Grow
Nov 23Shareholder Returns
| 690 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -5.4% | 7.2% | 2.9% |
| 1Y | 80.8% | 116.2% | 20.7% |
Return vs Industry: 690 underperformed the Hong Kong Biotechs industry which returned 116.2% over the past year.
Return vs Market: 690 exceeded the Hong Kong Market which returned 20.7% over the past year.
Price Volatility
| 690 volatility | |
|---|---|
| 690 Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in HK Market | 15.8% |
| 10% least volatile stocks in HK Market | 3.4% |
Stable Share Price: 690 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 690's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 504 | Frank Zhao | www.uni-bioscience.com |
Uni-Bio Science Group Limited, an investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in the People’s Republic of China. It operates through Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products segments. The company provides BOGUTAI, a disposable injection pen for the treatment of osteoporosis; GeneTime, a prescription biological drug for wound healing; GeneSoft, a therapeutic drug for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat invasive aspergillosis and fungal infections; and Boshutai, an oral medication for the treatment of diabetes.
Uni-Bio Science Group Limited Fundamentals Summary
| 690 fundamental statistics | |
|---|---|
| Market cap | HK$841.94m |
| Earnings (TTM) | HK$91.35m |
| Revenue (TTM) | HK$589.59m |
Is 690 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 690 income statement (TTM) | |
|---|---|
| Revenue | HK$589.59m |
| Cost of Revenue | HK$105.03m |
| Gross Profit | HK$484.56m |
| Other Expenses | HK$393.22m |
| Earnings | HK$91.35m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.015 |
| Gross Margin | 82.19% |
| Net Profit Margin | 15.49% |
| Debt/Equity Ratio | 26.0% |
How did 690 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 22:49 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Uni-Bio Science Group Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.